Tarceva

Showing 13 posts of 28 posts found.

Roche's Tarceva (erlotinib)

Tarceva fails to win NICE backing

June 30, 2011
Sales and Marketing NICE, Tarceva

NICE has decided not to recommend Roche’s Tarceva because of uncertainty over how long the lung cancer drug can extend …

Tarceva impresses again as it seeks to extend its EU licence

June 3, 2011
NSCLC, Roche, Tarceva

Roche and its partner OSI Pharmaceuticals have released another series of positive results for its lung cancer drug Tarceva as …

Erbitux (cetixumab)

Merck re-submits Erbitux to the EMA for lung cancer

March 30, 2011
Sales and Marketing EGFR, Erbitux, Iressa, Merck KGaA, NSCLC, Tarceva, lung cancer drugs, non-small cell lung cancer

Merck KGaA has re-submitted Erbitux’s lung cancer licence extension to the EMA after its first application to the regulator was …

NICE stands firm on Tarceva

March 11, 2011
Cancer, NICE, Roche, Tarceva, erlotinib

NICE has not recommended Roche’s lung cancer drug Tarceva because its effectiveness as a maintenance therapy remains unclear. NICE is …

Lung cancer cells

No magic bullet, but a growing arsenal against lung cancer

February 23, 2011
Research and Development ASA404, Cancer, Iressa, NSCLC, Tarceva, afatinib, crizotinib, figitumumab, lung cancer, non small cell lung cancer, non-small cell lung cancer

A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family …

Tarceva set for first line treatment

January 31, 2011
Sales and Marketing Iressa, NSCLC, Roche, Tarceva

Roche’s lung cancer treatment Tarceva has been shown to help patients as a first line treatment. An independent data monitoring …

Tarceva tablet

Roche set to challenge NICE Tarceva decision

November 25, 2010
Sales and Marketing NICE, Roche, Roche UK, Tarceva, erlotinib, lung cancer

NICE has again rejected Roche’s lung cancer drug Tarceva in its second round of draft guidance. Tarceva (erlotinib) was being …

Roche to develop diagnostic tools for Tarceva

November 23, 2010
Sales and Marketing Genzyme, NSCLC, Roche, Tarceva, diagnostic

Roche has obtained a worldwide sub-license from Genzyme to develop a diagnostic kit for the detection of specific mutations for …

Sutent disappoints in lung cancer

August 24, 2010
Research and Development, Sales and Marketing NSCLC, Pfizer, Sutent, Tarceva

Pfizer’s Sutent has failed to improve overall survival in lung cancer patients when combined with Roche’s Tarceva. Pfizer’s SUN 1087 …

Tarceva

NICE rejects Tarceva maintenance treatment

June 17, 2010
Sales and Marketing NICE, NSCLC, Roche, Tarceva, lung cancer

Roche’s Tarceva should not be used in lung cancer patients who have already been treated and whose disease remains stable, …

Tarceva gets nod for maintenance treatment

March 22, 2010
Sales and Marketing Tarceva, lung cancer

Tarceva looks set to gain approval in Europe to treat patients with non-small cell lung cancer whose disease remains stable …

NICE judges Tarceva too expensive for NHS

March 9, 2007
Sales and Marketing Tarceva, lung cancer

Roche's cancer drug Tarceva has been rejected by NICE for use against the most common form of lung cancer.The watchdog …

NICE to say no to Tarceva

November 17, 2006
Sales and Marketing NICE, Tarceva

Roche's new lung cancer treatment Tarceva looks set to be refused recommendation from NICE.Tarceva (erlotinib) is the first next-generation treatment …

The Gateway to Local Adoption Series

Latest content